Accovion GmbH, a full-service provider of clinical development services to the pharmaceutical, biotechnology and medical device industries and headquartered in Eschborn, Germany, has been voted a "Rising Star" and ranked the clinical research organisation in the top 10 of CROs in a recent survey.
“We are extremely pleased about this positive feedback and will make every effort to continue to consistently provide an excellent service to our clients to further ensure the continuation of these trusted partnerships”
Pharma IQ (www.pharma-iq.com), an international online community focusing on providing pharmaceutical professionals with industry knowledge, information and news from a variety of media, conducted the global survey to determine the "Top 10 Clinical Research Organisations in the Pharma and Biotech Industry" (http://www.pharma-iq.com/regulatory-legal/articles/top-10-clinical-research-organisations-in-the-phar/).
Pharmaceutical and biotech professionals within the circle of Pharma IQ's 50,000 registered members were asked about positive experiences with CROs. Regardless of CRO size or business longevity, the main objective was to find out which CROs consistently provide an excellent service to their clients.
The aim of the survey was to create a list of the top CROs in the market.
The list was not intended to be a directory of the biggest players in this space, but to highlight providers who have "gone the extra mile" for their clients. Criteria on which firms were assessed included:
• quality of services
• flexibility of partnership
• metrics structure
Over 70% of the participants said quality of services was the most important criteria when selecting a CRO. Other competencies that will draw a sponsor to a CRO include reputation and experience (60.5%) and cost (58%). Global reach and capacity as well as flexibility in the contract are also important considerations when choosing a CRO. Consistency, credibility, communication and trust were also mentioned as important criteria.
Almost 63% of those surveyed have a very good or good relationship with their CRO. Almost 24% cite their relationship as satisfactory; while only 5% are in unsatisfactory partnerships.
Results of the survey included 63% of respondents from small to medium organisations, over 26% work for medium-sized companies and 10% responded from large pharma organisations.
Less is more also appears to be the case as almost 87% of the survey respondents say that they are working with just one to ten CROs, while only 13% are working with between 11 and 25 organisations in this space.
Accovion has been voted a "Rising Star" and ranked within the top 10 CROs who work with the Pharma and Biotech Industry and match organisations' needs effectively according to the experiences of their partnerships.
Accovion would like to thank its clients for their vote of confidence! "We are extremely pleased about this positive feedback and will make every effort to continue to consistently provide an excellent service to our clients to further ensure the continuation of these trusted partnerships", said CEO Martin Schroeder.
BMI's influence on disease pathogenesis uncovered in new research